EMERGING APPROACHES TO COMBINATION THERAPIES IN AMD & DME (Company Presentation - Regeneron) panel from Healthegy's OIS@ASRS 2016:
Moderated By: Mark Humayun, MD
Presenter: David Boyer, MD - Regeneron
For more on Ophthalmology Innovation News & Events visit:
[ Ссылка ]
Regeneron Pharmaceuticals Inc. markets the highly successful anti-VEGF injection EYLEA (aflibercept), which is FDA approved for neovascular (wet) age-related macular degeneration (AMD), macular edema following retinal vein occlusion (RVO), and diabetic macular edema (DME) and diabetic retinopathy (DR) in patients with DME. Global EYLEA sales in 2015 totaled $4.1 billion, including OUS sales by Bayer. In the first half of 2016, EYLEA global sales increased 38% to $2.5 billion.
Retina specialist David Boyer, MD, provided an update regarding developments in combination therapy involving aflibercept, which may synergistically target different pathways and lead to increased efficacy and/or durability versus aflibercept alone. Regeneron is focusing on two new treatment targets: platelet derived growth factor receptor beta (PDGFR-beta) and angiopoietin2 (Ang2).
Read more about this panel here:
[ Ссылка ]
